Skip to main content

β-Cyclodextrin Complexes of Hydrolyzable Adamantanoyl-IUdR Prodrugs - Radioiodination and Biodistribution in Mice Bearing Implanted KBALB Tumours

Buy Article:

$68.00 + tax (Refund Policy)

Purpose: Iododeoxyuridine (IUdR, 1), a thymidine mimic with antiviral and anti-cancer properties, has a very short in vivo half-life which limits its efficacy as a clinical therapeutic or diagnostic agent. This work reports the radioiodination of 1 and its adamantanoyl prodrugs 2 and 3, the β-cyclodextrin (β-CyD) complexation of the radiolabelled prodrugs (2* and 3* to β-CyD-2* and β-CyD-3*, respectively), and the biodistribution of 1*, β-CyD-2* and β-CyD-3* in tumor- bearing mice. Methods: The C-5-tributylstannyl-UdR synthons 1-TBS, 2-TBS and 3-TBS were prepared and then radioiodinated with Na[125I]I in acetic acid and hydrogen peroxide to afford 125I-labelled 1*, 2* and 3*. Biodistribution studies of 1*, β-CyD-2* and β-CyD-3* were undertaken in Balb/c mice bearing implanted KBALB tumours. Results: 1-TBS, 2-TBS and 3-TBS were synthesized in 70, 45 and 29 % yield, respectively. Radioiododestannylation afforded 1*, 2* and 3* in 25.5 %, 80 % and 45 % radiochemical yield, respectively. In vivo biodistribution patterns for 1*, β-CyD-2* and β- CyD-3* after i.v. injection into mice differed only marginally. Conclusions: Inclusion complexes are formed between β- CyD and adamantane-IUdR conjugates. Despite the strong complexation between β-CyD and 2* or 3*, the radiobiodistribution patterns of for 1*, β-CyD-2* and β-CyD-3* were not markedly different from each other in tumourbearing mice. Thus, despite creation of inclusion compounds with high dissociation constants, additional development is required to exploit the β-CyD inclusion complex approach for improved delivery of nucleoside derivatives.





Keywords: KBALB tumours; adamantanoyl-nucleoside prodrugs; biodistribution; inclusion complexes; iododeoxyuridine; nucleosides; radioiodination; β-cyclodextrin

Document Type: Research Article

Publication date: 01 April 2009

More about this publication?
  • Current Radiopharmaceuticals publishes original research articles, letters, reviews, drug clinical trial studies and guest edited issues on all aspects of research and development of radiolabelled compound preparations. The scope of the journal covers the following areas: radio imaging techniques, therapies; preparation and application of radionuclide compounds including the incorporation of tracer methods used in scientific research and applications.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content